Resmetirom - Madrigal Pharmaceuticals
Alternative Names: MGL-3196; Rezdiffra; VIA-3196Latest Information Update: 19 Jan 2026
At a glance
- Originator Roche
- Developer Madrigal Pharmaceuticals
- Class Antihyperglycaemics; Antihyperlipidaemics; Chlorinated hydrocarbons; Ethers; Hepatoprotectants; Ketones; Nitriles; Pyridazines; Small molecules; Triazines
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-alcoholic steatohepatitis
- Discontinued Hyperlipoproteinaemia type IIa
Most Recent Events
- 29 Dec 2025 Madrigal Pharmaceuticals initiates enrolment in a phase II trial for Non-alcoholic steatohepatitis in USA and Canada (NCT07335601)
- 10 Nov 2025 Efficacy data from the phase-III MAESTRO-NASH trial in Non-alcoholic steatohepatitis released by Madrigal
- 10 Nov 2025 Pharamcodynamics, efficacy and adverse events data from phase III MAESTRO-NAFLD-1 trial in Non-alcoholic steatohepatitis released by Madrigal Pharmaceuticals